Wyeth Paying $491M To End Criminal, Civil Rapamune Cases

Law360, Chicago (July 30, 2013, 5:44 PM ET) -- Wyeth Pharmaceuticals Inc. has agreed to shell out $491 million to end a criminal action as well as civil False Claims Act cases alleging it illegally marketed its immunosuppressive drug Rapamune for unapproved uses, the U.S. Department of Justice said Tuesday.

Wyeth, which was acquired by Pfizer Inc. in 2009, also pled guilty to a criminal information alleging it misbranded the prescription drug in violation of the Federal Food, Drug and Cosmetic Act. Under that plea deal, which a federal court in Oklahoma has accepted, Wyeth...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers